The National Institute for Health and Care Excellence (NICE) has issued a preliminary recommendation against the routine NHS commissioning of…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
Gilead Sciences Finalizes $5 Billion Acquisition of Tubulis, Bolstering Oncology Pipeline with Advanced ADC Technology
Gilead Sciences has officially completed its acquisition of Tubulis, a prominent German biotechnology firm specializing in the development of next-generation…
Read More
Gilead Sciences Pledges Over 400,000 Doses of AmBisome to Combat Visceral Leishmaniasis, Extending Vital Global Health Partnership
Gilead Sciences has announced a significant commitment to global health, pledging over 400,000 doses of its vital antifungal medication, AmBisome…
Read More
Gilead Sciences Reports Robust Q1 2026 Performance Driven by Strong HIV Portfolio and Promising PrEP Launches
Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read More
Gilead Executive Sounds Alarm on Limited Innovation Investment Hindering Access to Advanced Therapies
The Netherlands faces significant challenges in ensuring timely patient access to life-changing advanced therapy medicinal products (ATMPs), a situation exacerbated…
Read More
